5.9
CiteScore
5.9
Impact Factor
Volume 38 Issue 8
Aug.  2011
Turn off MathJax
Article Contents
Article Navigation >  Journal of Genetics and Genomics  > 2011  >  38(8): 341-350

MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis

doi: 10.1016/j.jgg.2011.07.005
  • a 

    Laboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China

  • b 

    Key Laboratory of Medical Genetics (Harbin Medical University), Heilongjiang Higher Education Institutions, Harbin 150081, China

More Information
  • Corresponding author: E-mail address: fusongbin@yahoo.com (Songbin Fu)
  • Received Date: 2011-03-03
  • Accepted Date: 2011-07-18
  • Rev Recd Date: 2011-07-18
    • Available Online: 2011-07-22
  • Publish Date: 2011-08-20
    Abstract
  • The potentially functional polymorphism, SNP309, in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies showed inconclusive results. To obtain a more precise estimate of the association between MDM2 SNP309 and risk of cancer, we performed a meta-analysis of 70 individual studies in 59 publications that included 26,160 cases with different types of tumors and 33,046 controls. Summary odds ratios (OR) and corresponding 95% confidence intervals (CIs) were estimated using fixed- and random-effects models when appropriate. Overall, the variant genotypes were associated with a significantly increased cancer risk for all cancer types in different genetic models (GG vs. TT: OR, 1.123; 95% CI, 1.056–1.193; GG/GT vs. TT: OR, 1.028; 95% CI, 1.006–1.050). In the stratified analyses, the increased risk remained for the studies of most types of cancers, Asian populations, and hospital- /population-based studies in different genetic models, whereas significantly decreased risk was found in prostate cancer (GG vs. TT: OR, 0.606; 95% CI, 0.407–0.903; GG/GT vs. TT: OR, 0.748; 95% CI, 0.579–0.968). In conclusion, the data of meta-analysis suggests that MDM2 SNP309 is a potential biomarker for cancer risk.
    • These authors contributed equally to this work.
    FullText(HTML)
  • loading
    • References(91)
  • [1]
    Akisik, E., Yazici, H., Dalay, N. Mol. Biol. Rep., 1 (2010),pp. 343-348
    [2]
    Akkiz, H., Sumbul, A.T., Bayram, S. et al. Cancer Epidemiol., 34 (2010),pp. 448-452
    [3]
    Alazzouzi, H., Suriano, G., Guerra, A. et al. J. Med. Genet., 44 (2007),pp. 75-80
    [4]
    Alhopuro, P., Ylisaukko-Oja, S.K., Koskinen, W.J. et al. J. Med. Genet., 42 (2005),pp. 694-698
    [5]
    Arva, N.C., Gopen, T.R., Talbott, K.E. et al. A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells J. Biol. Chem., 280 (2005),pp. 26776-26787
    [6]
    Ashton, K.A., Proietto, A., Otton, G. et al. Gynecol. Oncol., 113 (2009),pp. 109-114
    [7]
    Asomaning, K., Reid, A.E., Zhou, W. et al. Clin. Cancer Res., 14 (2008),pp. 4010-4015
    [8]
    Boersma, B.J., Howe, T.M., Goodman, J.E. et al. J. Natl. Cancer Inst., 98 (2006),pp. 911-919
    [9]
    Bond, G.L., Hu, W., Levine, A. Cancer Res., 65 (2005),pp. 5481-5484
    [10]
    Bond, G.L., Hu, W., Bond, E.E. et al. Cell, 119 (2004),pp. 591-602
    [11]
    Campbell, I.G., Eccles, D.M., Choong, D.Y. Cancer Lett., 240 (2006),pp. 195-197
    [12]
    Capasso, M., Ayala, F., Avvisati, R.A. et al. J. Hum. Genet., 55 (2010),pp. 518-524
    [13]
    Chen, X., Sturgis, E.M., Lei, D. et al. Cancer Res., 70 (2010),pp. 7199-7208
    [14]
    Chen, Y.L., Chang, Y.S., Chang, J.G. et al. Anal. Bioanal. Chem., 394 (2009),pp. 1291-1297
    [15]
    Cho, Y.G., Choi, B.J., Song, J.H. et al. Neoplasma, 55 (2008),pp. 256-260
    [16]
    Chua, H.W., Ng, D., Choo, S. et al. BMC Cancer, 10 (2010),p. 88
    [17]
    Cox, D.G., Deer, D., Guo, Q. et al. Cancer Causes Control, 18 (2007),pp. 621-625
    [18]
    DerSimonian, R., Laird, N. Meta-analysis in clinical trials Control. Clin. Trials, 7 (1986),pp. 177-188
    [19]
    Dharel, N., Kato, N., Muroyama, R. et al. Clin. Cancer Res., 12 (2006),pp. 4867-4871
    [20]
    Egger, M., Davey Smith, G., Schneider, M. et al. Bias in meta-analysis detected by a simple, graphical test BMJ, 315 (1997),pp. 629-634
    [21]
    El Hallani, S., Marie, Y., Idbaih, A. et al. J. Neurooncol., 85 (2007),pp. 241-244
    [22]
    Ellis, N.A., Huo, D., Yildiz, O. et al. Blood, 112 (2008),pp. 741-749
    [23]
    Ezzikouri, S., El Feydi, A.E., Afifi, R. et al. Cancer Detect. Prev., 32 (2009),pp. 380-385
    [24]
    Freedman, D.A., Wu, L., Levine, A.J. Functions of the MDM2 oncoprotein Cell. Mol. Life Sci., 55 (1999),pp. 96-107
    [25]
    Gangwar, R., Mittal, R.D. Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population DNA Cell Biol., 29 (2010),pp. 349-356
    [26]
    Grochola, L.F., Muller, T.H., Bond, G.L. et al. Pancreas, 39 (2010),pp. 76-80
    [27]
    Hamid, S., Yang, Y.H., Peng, K.N. et al. Oral Oncol., 45 (2009),pp. 496-500
    [28]
    Haupt, Y., Maya, R., Kazaz, A. et al. Mdm2 promotes the rapid degradation of p53 Nature, 387 (1997),pp. 296-299
    [29]
    Hirata, H., Hinoda, Y., Kikuno, N. et al. Clin. Cancer Res., 13 (2007),pp. 4123-4129
    [30]
    Hirata, H., Hinoda, Y., Kikuno, N. et al. J. Urol., 181 (2009),pp. 1907-1912
    [31]
    Hirschhorn, J.N., Lohmueller, K., Byrne, E. et al. A comprehensive review of genetic association studies Genet. Med., 4 (2002),pp. 45-61
    [32]
    Hong, Y., Miao, X., Zhang, X. et al. Cancer Res., 65 (2005),pp. 9582-9587
    [33]
    Horikawa, Y., Nadaoka, J., Saito, M. et al. Oncol. Rep., 20 (2008),pp. 49-55
    [34]
    Hu, Z., Jin, G., Wang, L. et al. Cancer Epidemiol. Biomarkers Prev., 16 (2007),pp. 2717-2723
    [35]
    Hu, Z., Ma, H., Lu, D. et al. Int. J. Cancer, 118 (2006),pp. 1275-1278
    [36]
    Jun, H.J., Park, S.H., Lee, W.K. et al. Mol. Carcinog, 46 (2007),pp. 100-105
    [37]
    Kang, S., Wang, D.J., Li, W.S. et al. Int. J. Gynecol. Cancer, 19 (2009),pp. 572-577
    [38]
    Khatri, R.G., Navaratne, K., Weil, R.J. J. Neurosurg., 109 (2008),pp. 842-848
    [39]
    Kibel, A.S., Jin, C.H., Klim, A. et al. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma Prostate, 68 (2008),pp. 1179-1186
    [40]
    Kinyamu, H.K., Archer, T.K. Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression Mol. Cell. Biol., 23 (2003),pp. 5867-5881
    [41]
    Kubbutat, M.H., Jones, S.N., Vousden, K.H. Regulation of p53 stability by Mdm2 Nature, 387 (1997),pp. 299-303
    [42]
    Lang, A., Palmeback Wegman, P., Wingren, S. Rep, 22 (2009),pp. 575-579
    [43]
    Leu, J.D., Lin, I.F., Sun, Y.F. et al. World J. Gastroenterol., 15 (2009),pp. 5592-5597
    [44]
    Li, G., Zhai, X., Zhang, Z. et al. Carcinogenesis, 27 (2006),pp. 2028-2033
    [45]
    Lind, H., Zienolddiny, S., Ekstrom, P.O. et al. Int. J. Cancer, 119 (2006),pp. 718-721
    [46]
    Liu, G., Wheatley-Price, P., Zhou, W. et al. Int. J. Cancer, 122 (2008),pp. 915-918
    [47]
    Liu, J.N., Zhang, X.M., Guo, Y.L. et al. Chin. J. Oncol., 30 (2008),pp. 335-338
    [48]
    Ma, H., Hu, Z., Zhai, X. et al. Cancer Lett., 240 (2006),pp. 261-267
    [49]
    Mantel, N., Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease J. Natl. Cancer Inst., 22 (1959),pp. 719-748
    [50]
    Marcel, V., Palmero, E.I., Falagan-Lotsch, P. et al. J. Med. Genet., 46 (2009),pp. 766-772
    [51]
    Meissner Rde, V., Barbosa, R.N., Fernandes, J.V. et al. Cancer Detect. Prev., 31 (2007),pp. 371-374
    [52]
    Michael, D., Oren, M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol., 13 (2003),pp. 49-58
    [53]
    Millikan, R.C., Heard, K., Winkel, S. et al. Cancer Epidemiol. Biomarkers Prev., 15 (2006),pp. 175-177
    [54]
    Misra, C., Majumder, M., Bajaj, S. et al. Mol. Carcinog., 48 (2009),pp. 790-800
    [55]
    Mittelstrass, K., Sauter, W., Rosenberger, A. et al. BMC Cancer, 8 (2008),p. 113
    [56]
    Momand, J., Zambetti, G.P., Olson, D.C. et al. Cell, 69 (1992),pp. 1237-1245
    [57]
    Nakashima, M., Kondo, S., Shimizu, Y. et al. Acta Otolaryngol., 128 (2008),pp. 808-813
    [58]
    Nan, H., Qureshi, A.A., Hunter, D.J. et al. Cancer Causes Control, 20 (2009),pp. 171-179
    [59]
    Nunobiki, O., Ueda, M., Yamamoto, M. et al. Hum. Cell, 22 (2009),pp. 101-106
    [60]
    Ohmiya, N., Taguchi, A., Mabuchi, N. et al. J. Clin. Oncol., 24 (2006),pp. 4434-4440
    [61]
    Onat, O.E., Tez, M., Ozcelik, T. et al. Anticancer Res., 26 (2006),pp. 3473-3475
    [62]
    Park, S.H., Choi, J.E., Kim, E.J. et al. Lung Cancer, 54 (2006),pp. 19-24
    [63]
    Paulin, F.E., O’Neill, M., McGregor, G. et al. BMC Cancer, 8 (2008),p. 281
    [64]
    Perfumo, C., Parodi, S., Mazzocco, K. et al. Pediatr. Blood Cancer, 53 (2009),pp. 576-583
    [65]
    Petenkaya, A., Bozkurt, B., Akilli-Ozturk, O. et al. Anticancer Res., 26 (2006),pp. 4975-4977
    [66]
    Phillips, C.L., Gerbing, R., Alonzo, T. et al. Pediatr. Blood Cancer, 55 (2010),pp. 248-253
    [67]
    Pine, S.R., Mechanic, L.E., Bowman, E.D. et al. Cancer Epidemiol. Biomarkers Prev., 15 (2006),pp. 1559-1561
    [68]
    Schmidt, M.K., Reincke, S., Broeks, A. et al. Cancer Res., 67 (2007),pp. 9584-9590
    [69]
    Singh, V., Rastogi, N., Mathur, N. et al. Ann. Epidemiol., 18 (2008),pp. 48-57
    [70]
    Sotamaa, K., Liyanarachchi, S., Mecklin, J.P. et al. Clin. Cancer Res., 11 (2005),pp. 6840-6844
    [71]
    Stoehr, R., Hitzenbichler, F., Kneitz, B. et al. Br. J. Cancer, 99 (2008),pp. 78-82
    [72]
    Sun, Y.F., Leu, J.D., Chen, S.M. et al. BMC Cancer, 9 (2009),p. 13
    [73]
    Terry, K., McGrath, M., Lee, I.M. et al. Cancer Epidemiol. Biomarkers Prev., 17 (2008),pp. 983-986
    [74]
    Toffoli, G., Biason, P., Russo, A. et al. Clin. Cancer Res., 15 (2009),pp. 3550-3556
    [75]
    Tu, H.F., Chen, H.W., Kao, S.Y. et al. Radiother. Oncol., 87 (2008),pp. 243-252
    [76]
    Ueda, M., Yamamoto, M., Nunobiki, O. et al. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer Hum. Cell, 22 (2009),pp. 49-54
    [77]
    Walsh, C.S., Miller, C.W., Karlan, B.Y. et al. Gynecol. Oncol., 104 (2007),pp. 660-664
    [78]
    Wang, X., Yang, J., Ho, B. et al. Helicobacter, 14 (2009),pp. 114-119
    [79]
    Wasielewski, M., Nagel, J.H., Brekelmans, C. et al. Breast Cancer Res. Treat., 104 (2007),pp. 153-157
    [80]
    Wilkening, S., Bermejo, J.L., Hemminki, K. MDM2 SNP309 and cancer risk: a combined analysis Carcinogenesis, 28 (2007),pp. 2262-2267
    [81]
    Wilkening, S., Hemminki, K., Rudnai, P. et al. Br. J. Dermatol., 157 (2007),pp. 375-377
    [82]
    Wilkening, S., Bermejo, J.L., Burwinkel, B. et al. The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer Cancer Res., 66 (2006),pp. 646-648
    [83]
    Wu, Y.W., Prakash, K.M., Rong, T.Y. et al. Hum. Genet., 6 (2011),pp. 611-615
    [84]
    Xiao, M., Zhang, L., Zhu, X. et al. BMC Cancer, 10 (2010),p. 147
    [85]
    Xiong, X., Wang, M., Wang, L. et al. Leuk. Res., 33 (2009),pp. 1454-1458
    [86]
    Yang, M., Guo, Y., Zhang, X. et al. Carcinogenesis, 28 (2007),pp. 1996-2001
    [87]
    Yarden, R.I., Friedman, E., Metsuyanim, S. et al. Breast Cancer Res. Treat., 111 (2008),pp. 497-504
    [88]
    Zauberman, A., Flusberg, D., Haupt, Y. et al. Nucleic Acids Res., 23 (1995),pp. 2584-2592
    [89]
    Zhang, X., Miao, X., Guo, Y. et al. Hum. Mutat., 27 (2006),pp. 110-117
    [90]
    Zhang, Z., Zhang, R. p53-independent activities of MDM2 and their relevance to cancer therapy Curr. Cancer Drug Targets, 5 (2005),pp. 9-20
    [91]
    Zhou, G., Zhai, Y., Cui, Y. et al. Clin. Cancer Res., 13 (2007),pp. 2627-2633
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF

    Article Metrics

    Article views (82) PDF downloads (1) Cited by ()
    Proportional views
    Related

    Editorial Office

    Journal of Genetics and Genomics

    京ICP备09063187号-7

    No.1, West Beichen Road, Chaoyang District, Beijing 100101, P.R.China

    +86-10-64806528+86-10-64807786jgg@genetics.ac.cn

    Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return